Biologics and Biosimilars Market Report

Europe Biologics and Biosimilars Market Size, Status and Forecast 2014-2026

  • POSTDATE：Oct 18, 2019
  • PAGES：173
  • REPORT CODE：GMM329736
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Biologics and Biosimilars market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 4.1% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Biologics and Biosimilars Market Segmentations:

    By Player:

    • Innovent

    • AbbVie

    • Dong Bao

    • Amgen

    • Novartis

    • Sanofi-Aventis

    • United Laboratories

    • CP Guojian

    • Gelgen

    • Merck

    • Roche

    • Ganlee

    • Pfizer

    • Changchun High Tech

    • 3sbio

    • Johnson & Johnson

    • Biotech

    • Novo Nordisk

    • Eli Lilly

    By Type:

    • Monoclonal Antibodies

    • Interferon

    • Erythropoietin

    • Insulin

    • Vaccines

    By End-User:

    • Tumor

    • Diabetes

    • Cardiovascular

    • Hemophilia

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Biologics and Biosimilars Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Biologics and Biosimilars Market Size and Growth Rate of Monoclonal Antibodies from 2014 to 2026

    • 1.3.2 Europe Biologics and Biosimilars Market Size and Growth Rate of Interferon from 2014 to 2026

    • 1.3.3 Europe Biologics and Biosimilars Market Size and Growth Rate of Erythropoietin from 2014 to 2026

    • 1.3.4 Europe Biologics and Biosimilars Market Size and Growth Rate of Insulin from 2014 to 2026

    • 1.3.5 Europe Biologics and Biosimilars Market Size and Growth Rate of Vaccines from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Biologics and Biosimilars Market Size and Growth Rate of Tumor from 2014 to 2026

    • 1.4.2 Europe Biologics and Biosimilars Market Size and Growth Rate of Diabetes from 2014 to 2026

    • 1.4.3 Europe Biologics and Biosimilars Market Size and Growth Rate of Cardiovascular from 2014 to 2026

    • 1.4.4 Europe Biologics and Biosimilars Market Size and Growth Rate of Hemophilia from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Biologics and Biosimilars Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Biologics and Biosimilars by Major Types

      • 3.4.1 Market Size and Growth Rate of Monoclonal Antibodies

      • 3.4.2 Market Size and Growth Rate of Interferon

      • 3.4.3 Market Size and Growth Rate of Erythropoietin

      • 3.4.4 Market Size and Growth Rate of Insulin

      • 3.4.5 Market Size and Growth Rate of Vaccines

    4 Segmentation of Biologics and Biosimilars Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Biologics and Biosimilars by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Biologics and Biosimilars for Tumor

      • 4.4.2 Market Size and Growth Rate of Biologics and Biosimilars for Diabetes

      • 4.4.3 Market Size and Growth Rate of Biologics and Biosimilars for Cardiovascular

      • 4.4.4 Market Size and Growth Rate of Biologics and Biosimilars for Hemophilia

    5 Market Analysis by Major Regions

    • 5.1 Europe Biologics and Biosimilars Production Analysis by Top Regions

    • 5.2 Europe Biologics and Biosimilars Consumption Analysis by Top Regions

    • 5.3 Europe Biologics and Biosimilars Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Biologics and Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Biologics and Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.3 France Biologics and Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Biologics and Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Biologics and Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Biologics and Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Biologics and Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Biologics and Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Biologics and Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    6 Product Circulation of Biologics and Biosimilars Market among Top Countries

    • 6.1 Top 5 Export Countries in Biologics and Biosimilars Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Biologics and Biosimilars Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Biologics and Biosimilars Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Biologics and Biosimilars Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Biologics and Biosimilars Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Biologics and Biosimilars Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Biologics and Biosimilars Landscape Analysis

    • 7.1 Germany Biologics and Biosimilars Landscape Analysis by Major Types

    • 7.2 Germany Biologics and Biosimilars Landscape Analysis by Major End-Users

    8. UK Biologics and Biosimilars Landscape Analysis

    • 8.1 UK Biologics and Biosimilars Landscape Analysis by Major Types

    • 8.2 UK Biologics and Biosimilars Landscape Analysis by Major End-Users

    9. France Biologics and Biosimilars Landscape Analysis

    • 9.1 France Biologics and Biosimilars Landscape Analysis by Major Types

    • 9.2 France Biologics and Biosimilars Landscape Analysis by Major End-Users

    10. Italy Biologics and Biosimilars Landscape Analysis

    • 10.1 Italy Biologics and Biosimilars Landscape Analysis by Major Types

    • 10.2 Italy Biologics and Biosimilars Landscape Analysis by Major End-Users

    11. Spain Biologics and Biosimilars Landscape Analysis

    • 11.1 Spain Biologics and Biosimilars Landscape Analysis by Major Types

    • 11.2 Spain Biologics and Biosimilars Landscape Analysis by Major End-Users

    12. Poland Biologics and Biosimilars Landscape Analysis

    • 12.1 Poland Biologics and Biosimilars Landscape Analysis by Major Types

    • 12.2 Poland Biologics and Biosimilars Landscape Analysis by Major End-Users

    13. Russia Biologics and Biosimilars Landscape Analysis

    • 13.1 Russia Biologics and Biosimilars Landscape Analysis by Major Types

    • 13.2 Russia Biologics and Biosimilars Landscape Analysis by Major End-Users

    14. Switzerland Biologics and Biosimilars Landscape Analysis

    • 14.1 Switzerland Biologics and Biosimilars Landscape Analysis by Major Types

    • 14.2 Switzerland Biologics and Biosimilars Landscape Analysis by Major End-Users

    15. Turkey Biologics and Biosimilars Landscape Analysis

    • 15.1 Turkey Biologics and Biosimilars Landscape Analysis by Major Types

    • 15.2 Turkey Biologics and Biosimilars Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Landscape Analysis by Top Countries

      • 16.3.1 Denmark Biologics and Biosimilars Market Volume and Growth Rate

      • 16.3.2 Finland Biologics and Biosimilars Market Volume and Growth Rate

      • 16.3.3 Norway Biologics and Biosimilars Market Volume and Growth Rate

      • 16.3.4 Sweden Biologics and Biosimilars Market Volume and Growth Rate

      • 16.3.6 Iceland Biologics and Biosimilars Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Landscape Analysis by Top Countries

      • 17.3.1 Belgium Biologics and Biosimilars Market Volume and Growth Rate

      • 17.3.2 Netherlands Biologics and Biosimilars Market Volume and Growth Rate

      • 17.3.3 Luxembourg Biologics and Biosimilars Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Landscape Analysis by Top Countries

      • 18.3.1 Estonia Biologics and Biosimilars Market Volume and Growth Rate

      • 18.3.2 Latvia Biologics and Biosimilars Market Volume and Growth Rate

      • 18.3.3 Lithuania Biologics and Biosimilars Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Innovent

      • 19.1.1 Innovent Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 AbbVie

      • 19.2.1 AbbVie Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Dong Bao

      • 19.3.1 Dong Bao Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Amgen

      • 19.4.1 Amgen Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 Novartis

      • 19.5.1 Novartis Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    • 19.6 Sanofi-Aventis

      • 19.6.1 Sanofi-Aventis Company Profile and Development Status

      • 19.6.2 Market Performance

      • 19.6.3 Product and Service Introduction

    • 19.7 United Laboratories

      • 19.7.1 United Laboratories Company Profile and Development Status

      • 19.7.2 Market Performance

      • 19.7.3 Product and Service Introduction

    • 19.8 CP Guojian

      • 19.8.1 CP Guojian Company Profile and Development Status

      • 19.8.2 Market Performance

      • 19.8.3 Product and Service Introduction

    • 19.9 Gelgen

      • 19.9.1 Gelgen Company Profile and Development Status

      • 19.9.2 Market Performance

      • 19.9.3 Product and Service Introduction

    • 19.10 Merck

      • 19.10.1 Merck Company Profile and Development Status

      • 19.10.2 Market Performance

      • 19.10.3 Product and Service Introduction

    • 19.11 Roche

      • 19.11.1 Roche Company Profile and Development Status

      • 19.11.2 Market Performance

      • 19.11.3 Product and Service Introduction

    • 19.12 Ganlee

      • 19.12.1 Ganlee Company Profile and Development Status

      • 19.12.2 Market Performance

      • 19.12.3 Product and Service Introduction

    • 19.13 Pfizer

      • 19.13.1 Pfizer Company Profile and Development Status

      • 19.13.2 Market Performance

      • 19.13.3 Product and Service Introduction

    • 19.14 Changchun High Tech

      • 19.14.1 Changchun High Tech Company Profile and Development Status

      • 19.14.2 Market Performance

      • 19.14.3 Product and Service Introduction

    • 19.15 3sbio

      • 19.15.1 3sbio Company Profile and Development Status

      • 19.15.2 Market Performance

      • 19.15.3 Product and Service Introduction

    • 19.16 Johnson & Johnson

      • 19.16.1 Johnson & Johnson Company Profile and Development Status

      • 19.16.2 Market Performance

      • 19.16.3 Product and Service Introduction

    • 19.17 Biotech

      • 19.17.1 Biotech Company Profile and Development Status

      • 19.17.2 Market Performance

      • 19.17.3 Product and Service Introduction

    • 19.18 Novo Nordisk

      • 19.18.1 Novo Nordisk Company Profile and Development Status

      • 19.18.2 Market Performance

      • 19.18.3 Product and Service Introduction

    • 19.19 Eli Lilly

      • 19.19.1 Eli Lilly Company Profile and Development Status

      • 19.19.2 Market Performance

      • 19.19.3 Product and Service Introduction

    The List of Tables and Figures (Totals 69 Figures and 112 Tables)

    • Figure Product Picture

    • Figure Europe Biologics and Biosimilars Market Size and Growth Rate of Monoclonal Antibodies from 2014 to 2026

    • Figure Europe Biologics and Biosimilars Market Size and Growth Rate of Interferon from 2014 to 2026

    • Figure Europe Biologics and Biosimilars Market Size and Growth Rate of Erythropoietin from 2014 to 2026

    • Figure Europe Biologics and Biosimilars Market Size and Growth Rate of Insulin from 2014 to 2026

    • Figure Europe Biologics and Biosimilars Market Size and Growth Rate of Vaccines from 2014 to 2026

    • Figure Europe Biologics and Biosimilars Market Size and Growth Rate of Tumor from 2014 to 2026

    • Figure Europe Biologics and Biosimilars Market Size and Growth Rate of Diabetes from 2014 to 2026

    • Figure Europe Biologics and Biosimilars Market Size and Growth Rate of Cardiovascular from 2014 to 2026

    • Figure Europe Biologics and Biosimilars Market Size and Growth Rate of Hemophilia from 2014 to 2026

    • Figure Germany Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure UK Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure France Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Biologics and Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Biologics and Biosimilars Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Biologics and Biosimilars

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Biologics and Biosimilars by Different Types from 2014 to 2026

    • Table Consumption Share of Biologics and Biosimilars by Different Types from 2014 to 2026

    • Figure Market Size and Growth Rate of Monoclonal Antibodies

    • Figure Market Size and Growth Rate of Interferon

    • Figure Market Size and Growth Rate of Erythropoietin

    • Figure Market Size and Growth Rate of Insulin

    • Figure Market Size and Growth Rate of Vaccines

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Biologics and Biosimilars by Different End-Users from 2014 to 2026

    • Table Consumption Share of Biologics and Biosimilars by Different End-Users from 2014 to 2026

    • Figure Market Size and Growth Rate of Tumor

    • Figure Market Size and Growth Rate of Diabetes

    • Figure Market Size and Growth Rate of Cardiovascular

    • Figure Market Size and Growth Rate of Hemophilia

    • Table Europe Biologics and Biosimilars Production by Major Regions

    • Table Europe Biologics and Biosimilars Production Share by Major Regions

    • Figure Europe Biologics and Biosimilars Production Share by Major Countries and Regions in 2014

    • Table Europe Biologics and Biosimilars Consumption by Major Regions

    • Table Europe Biologics and Biosimilars Consumption Share by Major Regions

    • Table Germany Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table UK Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table France Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table Italy Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table Spain Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table Poland Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table Russia Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table Switzerland Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table Turkey Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Biologics and Biosimilars Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Biologics and Biosimilars Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Biologics and Biosimilars Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Biologics and Biosimilars Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table Germany Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Germany Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Germany Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table UK Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table UK Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table UK Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table UK Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table France Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table France Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table France Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table France Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Italy Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table Italy Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Italy Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Italy Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Spain Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table Spain Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Spain Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Spain Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Poland Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table Poland Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Poland Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Poland Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Russia Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table Russia Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Russia Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Russia Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table Switzerland Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Switzerland Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Switzerland Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table Turkey Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Turkey Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Turkey Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Biologics and Biosimilars Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Biologics and Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Biologics and Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Biologics and Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Biologics and Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Biologics and Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Biologics and Biosimilars Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Biologics and Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Biologics and Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Biologics and Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Biologics and Biosimilars Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Biologics and Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Biologics and Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Biologics and Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Table Company Profile and Development Status of Innovent

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Innovent

    • Figure Sales and Growth Rate Analysis of Innovent

    • Figure Revenue and Market Share Analysis of Innovent

    • Table Product and Service Introduction of Innovent

    • Table Company Profile and Development Status of AbbVie

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of AbbVie

    • Figure Sales and Growth Rate Analysis of AbbVie

    • Figure Revenue and Market Share Analysis of AbbVie

    • Table Product and Service Introduction of AbbVie

    • Table Company Profile and Development Status of Dong Bao

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Dong Bao

    • Figure Sales and Growth Rate Analysis of Dong Bao

    • Figure Revenue and Market Share Analysis of Dong Bao

    • Table Product and Service Introduction of Dong Bao

    • Table Company Profile and Development Status of Amgen

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Amgen

    • Figure Sales and Growth Rate Analysis of Amgen

    • Figure Revenue and Market Share Analysis of Amgen

    • Table Product and Service Introduction of Amgen

    • Table Company Profile and Development Status of Novartis

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novartis

    • Figure Sales and Growth Rate Analysis of Novartis

    • Figure Revenue and Market Share Analysis of Novartis

    • Table Product and Service Introduction of Novartis

    • Table Company Profile and Development Status of Sanofi-Aventis

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Sanofi-Aventis

    • Figure Sales and Growth Rate Analysis of Sanofi-Aventis

    • Figure Revenue and Market Share Analysis of Sanofi-Aventis

    • Table Product and Service Introduction of Sanofi-Aventis

    • Table Company Profile and Development Status of United Laboratories

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of United Laboratories

    • Figure Sales and Growth Rate Analysis of United Laboratories

    • Figure Revenue and Market Share Analysis of United Laboratories

    • Table Product and Service Introduction of United Laboratories

    • Table Company Profile and Development Status of CP Guojian

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of CP Guojian

    • Figure Sales and Growth Rate Analysis of CP Guojian

    • Figure Revenue and Market Share Analysis of CP Guojian

    • Table Product and Service Introduction of CP Guojian

    • Table Company Profile and Development Status of Gelgen

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Gelgen

    • Figure Sales and Growth Rate Analysis of Gelgen

    • Figure Revenue and Market Share Analysis of Gelgen

    • Table Product and Service Introduction of Gelgen

    • Table Company Profile and Development Status of Merck

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Merck

    • Figure Sales and Growth Rate Analysis of Merck

    • Figure Revenue and Market Share Analysis of Merck

    • Table Product and Service Introduction of Merck

    • Table Company Profile and Development Status of Roche

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Roche

    • Figure Sales and Growth Rate Analysis of Roche

    • Figure Revenue and Market Share Analysis of Roche

    • Table Product and Service Introduction of Roche

    • Table Company Profile and Development Status of Ganlee

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Ganlee

    • Figure Sales and Growth Rate Analysis of Ganlee

    • Figure Revenue and Market Share Analysis of Ganlee

    • Table Product and Service Introduction of Ganlee

    • Table Company Profile and Development Status of Pfizer

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Pfizer

    • Figure Sales and Growth Rate Analysis of Pfizer

    • Figure Revenue and Market Share Analysis of Pfizer

    • Table Product and Service Introduction of Pfizer

    • Table Company Profile and Development Status of Changchun High Tech

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Changchun High Tech

    • Figure Sales and Growth Rate Analysis of Changchun High Tech

    • Figure Revenue and Market Share Analysis of Changchun High Tech

    • Table Product and Service Introduction of Changchun High Tech

    • Table Company Profile and Development Status of 3sbio

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of 3sbio

    • Figure Sales and Growth Rate Analysis of 3sbio

    • Figure Revenue and Market Share Analysis of 3sbio

    • Table Product and Service Introduction of 3sbio

    • Table Company Profile and Development Status of Johnson & Johnson

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Johnson & Johnson

    • Figure Sales and Growth Rate Analysis of Johnson & Johnson

    • Figure Revenue and Market Share Analysis of Johnson & Johnson

    • Table Product and Service Introduction of Johnson & Johnson

    • Table Company Profile and Development Status of Biotech

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Biotech

    • Figure Sales and Growth Rate Analysis of Biotech

    • Figure Revenue and Market Share Analysis of Biotech

    • Table Product and Service Introduction of Biotech

    • Table Company Profile and Development Status of Novo Nordisk

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Novo Nordisk

    • Figure Sales and Growth Rate Analysis of Novo Nordisk

    • Figure Revenue and Market Share Analysis of Novo Nordisk

    • Table Product and Service Introduction of Novo Nordisk

    • Table Company Profile and Development Status of Eli Lilly

    • Table Sales, Revenue, Sales Price and Gross Margin Analysis of Eli Lilly

    • Figure Sales and Growth Rate Analysis of Eli Lilly

    • Figure Revenue and Market Share Analysis of Eli Lilly

    • Table Product and Service Introduction of Eli Lilly

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US